DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Overview
NASDAQ:DAWN - US23954D1090 - Common Stock
DAWN Key Statistics, Chart & Performance
The current stock price of DAWN is 7.2 USD. In the past month the price decreased by -0.41%. In the past year, price decreased by -48.9%.
DAWN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About DAWN
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 181 full-time employees. The company went IPO on 2021-05-27. The firm partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Company Info
DAY ONE BIOPHARMACEUTICALS I
2000 Sierra Point Parkway, Suite 501
Brisbane California CALIFORNIA US
CEO: Jeremy Bender
Employees: 182
Phone: 16504840899
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
What is the stock price of DAY ONE BIOPHARMACEUTICALS I today?
The current stock price of DAWN is 7.2 USD. The price increased by 3.15% in the last trading session.
What is the ticker symbol for DAY ONE BIOPHARMACEUTICALS I stock?
The exchange symbol of DAY ONE BIOPHARMACEUTICALS I is DAWN and it is listed on the Nasdaq exchange.
On which exchange is DAWN stock listed?
DAWN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DAY ONE BIOPHARMACEUTICALS I stock?
15 analysts have analysed DAWN and the average price target is 23.46 USD. This implies a price increase of 225.83% is expected in the next year compared to the current price of 7.2. Check the DAY ONE BIOPHARMACEUTICALS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DAY ONE BIOPHARMACEUTICALS I worth?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has a market capitalization of 737.50M USD. This makes DAWN a Small Cap stock.
How many employees does DAY ONE BIOPHARMACEUTICALS I have?
DAY ONE BIOPHARMACEUTICALS I (DAWN) currently has 182 employees.
What are the support and resistance levels for DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has a support level at 7.19 and a resistance level at 7.24. Check the full technical report for a detailed analysis of DAWN support and resistance levels.
Is DAY ONE BIOPHARMACEUTICALS I (DAWN) expected to grow?
The Revenue of DAY ONE BIOPHARMACEUTICALS I (DAWN) is expected to grow by 18.13% in the next year. Check the estimates tab for more information on the DAWN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DAWN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DAWN, evaluating the profitability, health, valuation and growth aspects
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Sales and EPS estimates to see what analysts future expectations are.
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Insider and Institutional Ownership to learn about the owners and their transactions.
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Chart to make your own analysis
- DAY ONE BIOPHARMACEUTICALS I (DAWN) Latest news and press-releases to stay up to date.
Does DAY ONE BIOPHARMACEUTICALS I (DAWN) stock pay dividends?
DAWN does not pay a dividend.
When does DAY ONE BIOPHARMACEUTICALS I (DAWN) report earnings?
DAY ONE BIOPHARMACEUTICALS I (DAWN) will report earnings on 2025-10-20, before the market open.
What is the Price/Earnings (PE) ratio of DAY ONE BIOPHARMACEUTICALS I (DAWN)?
DAY ONE BIOPHARMACEUTICALS I (DAWN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?
The outstanding short interest for DAY ONE BIOPHARMACEUTICALS I (DAWN) is 11.79% of its float. Check the ownership tab for more information on the DAWN short interest.
DAWN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DAWN. When comparing the yearly performance of all stocks, DAWN is a bad performer in the overall market: 88.65% of all stocks are doing better.
DAWN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DAWN. No worries on liquidiy or solvency for DAWN as it has an excellent financial health rating, but there are worries on the profitability.
DAWN Financial Highlights
Over the last trailing twelve months DAWN reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 15.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.3% | ||
| ROE | -20.61% | ||
| Debt/Equity | 0 |
DAWN Forecast & Estimates
15 analysts have analysed DAWN and the average price target is 23.46 USD. This implies a price increase of 225.83% is expected in the next year compared to the current price of 7.2.
For the next year, analysts expect an EPS growth of 29.39% and a revenue growth 18.13% for DAWN